Remibrutinib is an investigational oral BTK inhibitor designed to target chronic spontaneous urticaria (CSU), a form of severe, unexplained hives. By blocking specific immune pathways, it aims to reduce itch and wheals in patients who don't respond to antihistamines. Currently in late-stage trials, this once-daily therapy could offer a convenient, targeted alternative to injectable biologics, potentially improving quality of life for millions with refractory CSU.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends